Elranatamab: Clinical Trials

11 trials of Elranatamab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 recruiting, 2 active not recruiting. 11 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Recruiting 9, Active not recruiting 2
Phase 25Recruiting 5

Follow Elranatamab: new trials by email Literature Review of Elranatamab trials Research Report on Elranatamab

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Cemsidomide, Elranatamab - Multiple Myeloma (MM)
Phase 1RecruitingC4 Therapeutics, Inc.602026-02-062026-10-30
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Elranatamab, Mezigdomide, Dexamethasone - Multiple Myeloma
Phase 1 / Phase 2RecruitingCelgene622025-10-072026-09-02
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma
Phase 1RecruitingDavid Avigan252025-01-312026-05-07
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM)
Phase 1 / Phase 2RecruitingYOUNGIL KOH752024-11-262025-12-03
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Elranatamab - AL Amyloidosis
Phase 1 / Phase 2RecruitingDana-Farber Cancer Institute492024-11-012026-08-19
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
BMS-986393, Alnuctamab, Mezigdomide - Multiple Myeloma
Phase 1RecruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company1872024-02-222026-07-16
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Elranatamab, Iberdomide - Multiple Myeloma
Phase 1Active not recruitingPfizer1002024-02-202026-09-15
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AZD0305, Elranatamab, Pomalidomide - Multiple Myeloma
Phase 1 / Phase 2RecruitingAstraZeneca2262023-12-052026-10-30
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Cevostamab, Elranatamab, Tocilizumab - Relapsed or Refractory Multiple Myeloma
Phase 1RecruitingGenentech, Inc.1202023-08-102026-11-05
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Elranatamab, Carfilzomib, Maplirpacept - Multiple Myeloma
Phase 1Active not recruitingPfizer592022-12-142026-08-13
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CCS1477, Pomalidomide, Dexamethasone - Haematological Malignancy, Acute Myeloid Leukemia
Phase 1 / Phase 2RecruitingCellCentric Ltd.2502019-08-092026-06-24

Conditions studied

Multiple Myeloma (10)  ·  Recurrence (4)  ·  Bites and Stings (1)  ·  Hematologic Neoplasms (1)  ·  Immunoglobulin Light-chain Amyloidosis (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell, Peripheral (1)

Sponsors

Pfizer (2)  ·  AstraZeneca (1)  ·  C4 Therapeutics, Inc. (1)  ·  Celgene (1)  ·  CellCentric Ltd. (1)  ·  Dana-Farber Cancer Institute (1)  ·  David Avigan (1)  ·  Genentech, Inc. (1)  ·  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1)  ·  YOUNGIL KOH (1)

Countries

United States (9)  ·  Canada (4)  ·  Australia (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  China (2)  ·  France (2)  ·  Germany (2)  ·  Israel (2)  ·  South Korea (2)  ·  Brazil (1)  ·  Greece (1)  ·  Japan (1)  ·  Norway (1)  ·  Singapore (1)

Top investigators

David Avigan, MD (1)  ·  Giada Bianchi (1)  ·  Tim Somervaille (1)

NIH funding

2023 (2), 2025 (1)